Ex­clu­sive: Two M&A deals and $9B lat­er, Lon­nie Moul­der is ramp­ing up his lat­est biotech start­up. And this one comes with glob­al vi­sion built in

Lon­nie Moul­der may have been in silent run­ning mode in the 2 years since he closed the $5 bil­lion sale of Tesaro to Glax­o­SmithK­line. But he hasn’t been idle.

To­day dur­ing the Chi­na Health­care In­vest­ment Con­fer­ence in Shang­hai, where End­points News is play­ing a co-spon­sor role, Moul­der’s tak­ing the wraps off a biotech start­up he’s put to­geth­er that has as­sem­bled a pipeline with 7 drugs in it, a plan to add sev­er­al more ther­a­pies and a quick vault in­to the clin­ic for a com­pa­ny with a small but fast-ex­pand­ing team that is grow­ing roots in Chi­na and the US — with Eu­rope soon to be added to its glob­al frame.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER